Alzamend Neuro™ Launches Pursuit to Secure FDA IND and First Stage Clinicals

Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has selected TAMM Net of Marietta, GA to lead its FDA regulatory application and oversight efforts including the successful filing of a FDA IND application and resulting in FDA approval to conduct a First Stage Clinical Trial for CAO22W.

FULL PRESS RELEASE